METHOTREXATE 2.5 MG TABLET

What it is

METHOTREXATE 2.5 MG TABLET is how the CMS NADAC file names this product. The FDA NDC Directory lists it as “methotrexate” and “methotrexate sodium”, as its NDCs’ listings variously write the nonproprietary name.

FDA gives its dosage form as tablet and its route as oral.

FDA lists 12 labelers (the companies named on the label) for its NDCs, among them Hikma Pharmaceuticals USA Inc., Mylan Pharmaceuticals Inc. and Teva Pharmaceuticals USA, Inc.

FDA’s Established Pharmacologic Class for it is Folate Analog Metabolic Inhibitor.

The NADAC file of 2026-10-14 prices it under 17 NDCs (National Drug Codes); the FDA directory lists 15 of them.

NADAC classes it as a generic drug (rate-setting class G), and does not mark it as sold over the counter.

What pharmacies pay

Pharmacies pay $4.73 for 30 tablets (30 × $0.15774 per EA, rounded to the cent), by the CMS NADAC file of 2026-10-14; that price took effect on 2026-09-23. That is what pharmacies pay their suppliers, not what they charge you.

NADAC’s explanation code for it: 1, calculated from the most recently completed pharmacy survey.

What NADAC measures · Why 30 tablets · NADAC explanation codes

The 12 labelers

Other strengths, forms and brands

13 other products in the NADAC file share an FDA nonproprietary name with METHOTREXATE 2.5 MG TABLET.

Part D is one average per brand and generic name, over every strength and form.

CMS NADAC · nadac-national-average-drug-acquisition-cost-20261014.csv · eff. between 2026-01-01 and 2026-09-23 (4 dates) · as of 2026-10-14 · retrieved 2026-10-17

Medicare Part D · DSD_PTD_RY26_P04_V10_DY24_BGM.csv · eff. 2024-01-01 to 2024-12-31 · as of 2026-06-25 · retrieved 2026-10-18

OpenBill calculation · october-2026-medicare-part-b-payment-limit-files-final.zip + october-2026-ndc-hcpcs-crosswalk-final.zip · Part B limit 2026-10-01 to 2026-12-31 (file of 2026-09-17, retrieved 2026-10-18) · Part B crosswalk 2026-10-01 to 2026-12-31 (file of 2026-09-17, retrieved 2026-10-18)

Compared with its class

The middle of its 17 NDCs’ NADAC prices is $0.15774 per EA filed.

Of the 3 other products in FDA’s Folate Analog Metabolic Inhibitor class priced per EA, 3 have a higher middle NADAC price and 0 a lower one. The one in the middle is TREXALL 7.5 MG TABLET, at $36.20914 per EA filed (eff. 2026-02-18).

Prices are compared per unit, whatever the strength or dose, and a class is not a list of substitutes.

CMS NADAC · nadac-national-average-drug-acquisition-cost-20261014.csv · eff. 2026-02-18, 2026-09-23 · as of 2026-10-14 · retrieved 2026-10-17

How the class comparison works

What Medicare paid

Medicare Part B’s payment limit for HCPCS J8610, for 2026-10-01 to 2026-12-31, comes to $4.71 for 30 tablets, or $0.157 per EA once converted to NADAC’s unit for this product.

Medicare Part B pays for this oral drug at a pharmacy only in specific circumstances CMS sets for this code; most prescriptions are paid by Part D.

The patient’s share under Part B (coinsurance, 20% of the limit, before deductibles and other coverage) is $0.0314 per 2.5 MG.

11 of the product’s 17 NDCs have this Medicare figure; the other 6 do not, and the interactive card says why for each.

Medicare's price is not your price.

What the Part B payment limit is · Converting it to the NADAC unit · How the spread is worked out

What to ask at the counter

None of these figures is your price: what you pay depends on your pharmacy, your insurance, coupons and discounts.

• What is your cash price for 30 tablets? Is it lower than what I would pay through my insurance?
• If you have Medicare Part B: is this drug covered for me in this setting, and what is my share?
• These are questions about price, not medical advice. Do not change or stop a medicine without talking to your prescriber or pharmacist.